ライフサイエンスコーパス: patent

1 ging from zero (total occlusion) to 8 (fully patent).

2 ndothelialized within one month and remained patent.

3 arch articles (80%) link forward to a future patent.

4 d, leaving the large vessels of the fibroids patent.

5 a grant and its propensity to be cited by a patent.

6 al vein maintaining the right hepatic artery patent.

7 d disposition data and bioactivity data from patents.

8 rate articles that are subsequently cited by patents.

9 n lymph node biopsies of follicular lymphoma patents.

10 to control blood glucose levels in diabetic patents.

11 om scientific articles and, increasingly, US patents.

12 Food and Drug Administration approval and by patents.

13 action roles and yields, from pharmaceutical patents.

14 erformed within 3 months of diagnosis in 561 patents.

15 s well as so-called prophetic compounds from patents.

16 impact publications, and 14% fewer follow-on patents.

17 Office may hear new challenges to stem cell patents.

18 wondered how genes were ever the subjects of patents.

19 he data are gathered from the literature and patents.

20 st time, that isolated human genes cannot be patented.

21 n public research investments and subsequent patenting.

22 citation impact in all fields of science and patenting.

23 Eligible patients from the PATENT-1 study entered the PATENT-2 open-label extension

24 patients from the PATENT-1 study entered the PATENT-2 open-label extension, which will continue until

25 rial hypertension receiving riociguat in the PATENT-2 study.

26 396 patients entered PATENT-2, of whom 197 patients were receiving riociguat

27 efficacy data from the final data cutoff of PATENT-2, where most patients had received at least 2 ye

28 Riociguat was well tolerated in PATENT-2.

29 Similarly, most patents (61%) link backward to a prior research article.

30 usculature maintaining the architecture of a patent airway conduit and abdominal wall and internal in

31 ain mechanism of airway closure in initially patent airways, which can occur at more than one site in

32 These patents, along with other biological patents, generated

33 We have recently patented an unprecedented stereospecific N -> O phosphin

34 progression rates were then compared between patent and occluded vessels for each vessel type with Fi

35 , as evidenced by the recent outpour of both patent and primary reports.

36 the household and malaria infection status (patent and subpatent) of all-aged individuals.

37 hy-Smith America Invents Act (AIA), the U.S. Patent and Trademark Office may hear new challenges to s

38 substantial and fruitful connections between patenting and prior scientific inquiry.

39 We study 4.8 million U.S. patents and 32 million research articles to determine th

40 the national population, but for 48% of its patents and 33% of its gross domestic product.

41 s of MEE and CO did not differ between HFrEF patents and age-matched volunteers.

42 towards the daily use, analysing the various patents and applications reported to date.

43 evidenced by a wealth of graphene research, patents and applications.

44 st prices are issues of regulatory approval, patents and intellectual property, assessment of value a

45 Branded drug companies have patents and market exclusivity periods in most industria

46 ary text input (e.g. scholarly publications, patents and medical records) in multiple formats (e.g. B

47 Patents and publications (1981-2011) were evaluated usin

48 Here we analyse more than 65 million papers, patents and software products that span the period 1954-

49 Our analysis uses 1.8 million US patents and their citation properties to map the innovat

50 We also consider performance data from patents and unpublished sources so as to define the scop

51 All BVS were widely patent, and binary restenosis rate was 2% (the only rest

52 ese many activities (scientific publication, patenting, and industrial production in different sector

53 ata on the citation of academic articles and patents, and on the online attention received by songs,

54 4.4% of the grants resulted in patents, and these were associated with higher award amo

55 A review of the scientific literature, patents, and web articles revealed several approaches be

56 ions, there is a steady increase in costs of patented anticancer agents over time.

57 the IMA ostium, and the number of additional patent aortic side branches from the aneurysm sac.

58 0 medicinal chemistry-based publications and patents appearing to date, leading to 38 clinical candid

59 s, the bulk of the effect of NIH research on patenting appears to be indirect.

60 The patent application number is PCT/US2016/036650'.

61 inaccessible in 13 countries where medicine patents are protected, the additional cost of the ambiti

62 The persistence of a patent arteriovenous fistula (AVF) after transplantation

63 infectious to mosquitoes as individuals with patent (asexual parasite) infection.

64 e, open and timely set of annotated compound-patent associations, complemented with sophisticated com

65 is a pressing need shared by researchers and patent attorneys from different chemical disciplines.

66 Elective ligation of patent AVF in adults with stable kidney transplant funct

67 35%), antibiotics (46%), chlorhexidine (8%), patent blue dye (8%) and others (8%).

68 ne (E127), Red 2G (E128), Allura Red (E129), Patent Blue V (E131), Indigo Carmine (E132), Brilliant B

69 Off-patent brand-name drugs (cost: >$10 000) were covered by

70 dicare Part D spending dashboard and any off-patent brand-name drugs that incurred more than $10 000

71 e programs and the coverage of expensive off-patent brand-name drugs vs substitutable generic drugs.

72 ully patent, minimal, or no reflux; (b) >50% patent but some reflux; (c) some patency but >50% reflux

73 ferent reaction types used in pharmaceutical patents but a trend toward lower median yield for some o

74 Although policy-makers often focus on direct patenting by academic scientists, the bulk of the effect

75 No association between patent collateral circulation and favorable outcome was

76 ngi establish NSC319726 as a repurposed, off-patent compound that has potential antifungal activity.

77 ents (30 per group with occluded [cases] and patent [control subjects] grafts) on plasma samples coll

78 l US performed three weeks later confirmed a patent covered stent and complete aneurysmal exclusion.

79 procedure, showed an excluded aneurysm and a patent covered stent.

80 and histologic analyses were consistent with patent craniofacial sutures.

81 conversely, practicing surgeon PIs affected patent creation negatively (OR 0.31; 95% CI 0.11-0.85; P

82 0.001] was associated with improved odds of patent creation; conversely, practicing surgeon PIs affe

83 BMP10 that correlated with the presence of a patent DA.

84 Using historical patent data, we show that the spatial concentration of c

85 ormation from different sources (literature, patent databases) and novel sequence data to identify un

86 The US share of life science patents declined from 57% (1981) to 51% (2011), as did t

87 find that about 10% of NIH grants generate a patent directly but 30% generate articles that are subse

88 t cases, and discuss the future of stem cell patent disputes.

89 bilities against the compound repository and patent document corpus; given the wealth of knowledge hi

90 pus; given the wealth of knowledge hidden in patent documents, analysis of SureChEMBL data has immedi

91 rom the full text, images and attachments of patent documents.

92 million compounds extracted from 14 million patent documents.

93 DSF is an off-patent drug molecule.

94 nctionalization for the rapid synthesis of a patented drug candidate.

95 Screening a custom library of 100 off-patent drugs for synergistic activity with pitavastatin

96 ts of drug research, including resources for patented drugs, their side effects, withdrawn drugs, and

97 7, 47%), atrial septal defects (20/47, 43%), patent ductus arteriosus (16/47, 34%), persistent left s

98 ds ratio [AOR], 0.81; 95% CI, 0.67-0.98) and patent ductus arteriosus (AOR, 0.74; 95% CI, 0.62-0.89).

99 consensus for the screening and treatment of patent ductus arteriosus (PDA) in extremely preterm infa

100 Nonsyndromic patent ductus arteriosus (PDA) is a common congenital he

101 Patent ductus arteriosus (PDA) is associated with increa

102 Observational studies have associated patent ductus arteriosus (PDA) ligation among preterm in

103 7-year-old female with a history of neonatal patent ductus arteriosus (PDA) ligation, left-sided chor

104 Patent ductus arteriosus (PDA) poses a diagnostic and th

105 associated with growth after days 1-8, with patent ductus arteriosus (PDA) showing negative associat

106 od flow may undergo palliation with either a patent ductus arteriosus (PDA) stent or a modified Blalo

107 ulmonary blood flow, initial palliation with patent ductus arteriosus (PDA) stent or modified Blalock

108 ve (BAV), coarctation of the aorta (CoA) and patent ductus arteriosus (PDA).

109 tal defect (aORs ranging from 1.29 to 2.17), patent ductus arteriosus [aORs = 1.54, 1.63; 95% confide

110 11 (c.4599+1delG) was identified in familial patent ductus arteriosus and found to disrupt normal spl

111 2000-2001 to 7.5 per mille in 2012-2013, of patent ductus arteriosus from 1.9 per mille to 4.1 per m

112 e presence of a haemodynamically significant patent ductus arteriosus had a significant independent i

113 Patent ductus arteriosus ligation among preterm neonates

114 tricular leukomalacia, chronic lung disease, patent ductus arteriosus requiring surgery, retinopathy

115 e presence of a haemodynamically significant patent ductus arteriosus results in a deeper impairment

116 Medical treatment for patent ductus arteriosus significantly decreased over th

117 f infants who required surgical closure of a patent ductus arteriosus was lower in the budesonide gro

118 al CHD, 4 with atrial septal defects, 2 with patent ductus arteriosus, 2 with tetralogy of Fallot, an

119 A concomitant cardiac lesion, for example, patent ductus arteriosus, and aortic cross-clamp time we

120 via imaging (secundum atrial septal defect, patent ductus arteriosus, ventricular septal defect, pul

121 cts, persistent left superior vena cava, and patent ductus arteriosus, were present in 32% of patient

122 s of death or bronchopulmonary dysplasia and patent ductus arteriosus.

123 unts, H-type portal-caval, portohepatic, and patent ductus venosus patients had a successful 1-stage

124 Here we use data on scientific papers, patents, employment and gross domestic product, for 353

125 FFR was measured in all major patent epicardial coronary arteries with a visual stenos

126 increasingly being used to expand access to patented essential medicines in low-income and middle-in

127 Our patent essentially concerns a medical needleless device,

128 -33) months, all venous reconstructions were patent except for 1 tubular graft (97%).

129 demonstrate that generic medications without patent exclusivity are not guaranteed to have durably lo

130 g reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competiti

131 ably, some drugs from this candidate set are patent-expired and currently neglected for PrEP repurpos

132 ly investigated long-acting formulations, or patent-expired drugs.

133 These are associated with not only expanding patent extraction but also increasingly large vendor col

134 were 18 to 40 years of age, had at least one patent fallopian tube and a normal uterine cavity, and h

135 omen 18 to 40 years of age with at least one patent fallopian tube were randomly assigned to ovarian

136 ry but the target one, we screened 1.280 off-patent FDA-approved drug for GraXRS inhibition.

137 fusion had no effect on the EPR in rats with patent femoral arteries (n = 9).

138 infusion on the pressor reflex in rats with patent femoral arteries.

139 Immune modulation is a hallmark of patent filarial infection, including suppression of anti

140 with STEMM achievement measured variously as patents filed or licensed, companies founded, number of

141 nd playing are significantly correlated with patent filings and licenses, and others are correlated w

142 nation was entirely normal otherwise, with a patent filtration and diffuse bleb as confirmed with ant

143 the new law affects challenges to stem cell patents, focusing on two recent cases, and discuss the f

144 the course of in vitro culture and remained patent for 3 days after orthotopic transplantation in ra

145 n of oxetane derivatives appearing in recent patents for medicinal chemistry applications.

146 The patents for the first approved treatments for relapsing-

147 rsus 36.5% in patient with ECs; P<0.001) and patent foramen ovale (4.6% versus 13.5%; P=0.002).

148 ned patients 18 to 60 years of age who had a patent foramen ovale (PFO) and had had a cryptogenic isc

149 dary prevention of embolism in patients with patent foramen ovale (PFO) and otherwise unexplained isc

150 Patent foramen ovale (PFO) can be detected in up to 43%

151 Patent foramen ovale (PFO) closure is the gold standard

152 Trials of patent foramen ovale (PFO) closure to prevent recurrent

153 t is observed in up to 25% of patients after patent foramen ovale (PFO) closure, but its long-term in

154 Patent foramen ovale (PFO) has been associated with migr

155 The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurren

156 Patent foramen ovale (PFO) is associated with cryptogeni

157 ive effectiveness of percutaneous closure of patent foramen ovale (PFO) plus medical therapy versus m

158 pothesized that paradoxical embolism through patent foramen ovale (PFO) should be the main mechanism.

159 o right-to-left shunted blood flow through a patent foramen ovale (PFO) would not be cooled.

160 in selected symptomatic patients, closure of patent foramen ovale after cryptogenic stroke, treatment

161 Structural heart disease and a patent foramen ovale are strongly associated with the pr

162 anticoagulation for atrial fibrillation, and patent foramen ovale closure.

163 rocedure (11%), aortic valve procedure (9%), patent foramen ovale or atrial septal defect closure (23

164 Whether closure of a patent foramen ovale reduces the risk of recurrence of i

165 eart disease, presence of left common trunk, patent foramen ovale, and time for atrial fibrillation d

166 uding occult paroxysmal atrial fibrillation, patent foramen ovale, aortic arch atherosclerosis, atria

167 When pulmonary embolism coexists with a patent foramen ovale, increased pressure in the right at

168 DVT and paradoxical embolism due to existing patent foramen ovale.

169 es with isolated atrial septal defect and/or patent foramen ovale.

170 readily, in association with more prevalent patent gametocytemia.

171 opulation, harbor a third of infections with patent gametocytes between May and August, when transmis

172 These patents, along with other biological patents, generated substantial social and political crit

173 n of this preexisting network structure with patent growth in upstream technology fields has strong p

174 which should have included the following: 'A patent has been applied for by Emory University with F.E

175 time to achieve complete hemostasis and less patent hemostasis rate.

176 Patent hemostasis were less frequently obtained and time

177 0 s, ACT between 150 and 249 s, ACT >250 s), patent hemostasis with reverse Barbeau test was attempte

178 hin the ablation zone (P = .02) but not with patent hepatic (P = .57) or portal (P = .14) veins.

179 ion rates were significantly correlated with patent hepatic arteries within the ablation zone (P = .0

180 t of 8 patients (75%) were asymptomatic with patent hepatic artery, which was confirmed by multislice

181 peptide, acrophiarin, was circumscribed in a patent in 1979.

182 The RA was found to be patent in 24 cases (84.8% patency).

183 P2 KO arteries grafted into WT mice remained patent in vivo.

184 urther, analyzing about 3.85 million granted patents in China (1990-2013), we find that provinces wit

185 imately successful campaign to overturn gene patents in court.

186 During early healing, patents in the azithromycin group exhibited a significan

187 found to be predictive of future periods of patent infection and in membrane feeding studies, indivi

188 e mutant was associated with higher risks of patent infection in peripheral blood (adjusted prevalenc

189 nterval [CrI] 0.35-20.45; P < 0.001) odds of patent infections (according to the DHS data) and 5.13 g

190 The association of patent infections at enrollment with low birth weight su

191 ion with OV-16 increased the sensitivity for patent infections to 94%.

192 The tool identified both prepatent and patent infections using Schistosoma japonicum DNA isolat

193 a's pilot emissions trading, based on latest patenting information and a quasi-experimental design.

194 ges in mean monthly costs for a cohort of 24 patented, injectable anticancer drugs that were approved

195 lting/services, honoraria, expenses, royalty/patent/intellectual property, and other disclosures.

196 ermine the minimum citation distance between patented inventions and prior scientific advances.

197 of preparation, physicochemical properties, patented inventions and recent advances of these micelle

198 An analysis of the emerging patent landscape of gene therapies under development, fo

199 earchers (and patent offices) began to apply patent-law logic to genes themselves.

200 frequent in thrombosed lesions compared with patent lesions (70% vs. 43%, p = 0.045) and maximal unde

201 s significantly greater in thrombosed versus patent lesions.

202 to screen and characterize FDA-approved, off-patent library drugs for anti-Mycobacterium tuberculosis

203 Using data on patents linked to U.S. National Institutes of Health (NI

204 The data are extracted from the patent literature according to an automated text and ima

205 KDMs, KDM2-7), focusing on the academic and patent literature from 2014 to date.

206 ents for the treatment of IPF along with the patent literature from the past 10 years.

207 a quinoline series recently disclosed in the patent literature into a chemotype previously used for t

208 rthermore, integration of these catalysts in patent literature is also disclosed highlighting the ver

209 inantly works which can only be found in the patent literature, but should be of equal interest to bo

210 cements, with a focus on both scientific and patent literature.

211 ratory, and the other is a compound from the patent literature.

212 c modulators disclosed in the scientific and patent literature.

213 gonists and summarizes the peer reviewed and patented literature.

214 these instances have been central issues in patent litigations.

215 h self-expandable metal stents (SEMS) remain patent longer than plastic stents, they are more expensi

216 ood loss, whereas the umbilical vein remains patent longer.

217 ccluded, significantly stenosed (>/=50%), or patent (<50% stenosis).

218 ta-catenin at the plasma membrane, induced a patent lumen in CRC spheroids, and slowed CRC cell invas

219 data, integrating household information and patent malaria infection, recent fever, and recent treat

220 Approximately 256 traditional Chinese patent medicines, containing Aristolochiaceous materials

221 were performed for relevant clinical trials, patents, meeting abstracts, and awards of NIH funding.

222 NAs) with potential utility as biomarkers of patent (mf (+) ) L. loa infection.

223 rimal syringing and categorized as (a) fully patent, minimal, or no reflux; (b) >50% patent but some

224 n-Friendly (GF) technology (Italian priority patent n degrees 102015000084813 filed on 17th December

225 mors we noted the emergence of CD31-negative patent neovessels and a concomitant loss of tumor homing

226 try level: the global trade network, and the patent network in different technological domains.

227 -(hydroxymethyl)oxetane (EAMO) repeat units (Patent No.: US 9,421,276) via the linker 3,3'-dithiodipr

228 tool extracting strain related publications, patents, nucleotide sequences and genome information fro

229 Once the patent of a brand-name drug expires, generic drugs are c

230 sequence came to fruition, researchers (and patent offices) began to apply patent-law logic to genes

231 ad evidence of a patent ostium and 100% were patent on lacrimal irrigation.

232 Myriad Genetics, a company with patents on BRCA1 and BRCA2, two genes critical to assess

233 Following the expiration of the patents on fused-filament-fabrication (FFF), the availab

234 ility and outcomes of retrograde CTO PCI via patent or occluded saphenous vein graft.

235 ly, all coronary bypass grafts were rated as patent or occluded.

236 n within a cohort of commonly prescribed off-patent oral antibiotics.

237 This inexpensive and off-patent oral medication is a promising adjunctive antifun

238 89% of the cases (n = 58) had evidence of a patent ostium and 100% were patent on lacrimal irrigatio

239 accurately predicts out-of-sample paper and patent outcomes.

240 new data to track publication, citation, and patenting outcomes associated with more than 130,000 res

241 reactions and molecules retrieved from U.S. patents over the past 40 years (1976-2015).

242 preterm labour was also more common in these patents (p < 0.05).

243 Yet, advances directly along the patent-paper boundary are notably more impactful within

244 3 chloroquine arm subjects displayed delayed patent parasitemia (P = .01) but not sterile protection,

245 3 chloroquine arm subjects displayed delayed patent parasitemia (p=0.01) but not sterile protection,

246 with PfUIS3 can induce a consistent delay in patent parasitemia across mouse strains and against chim

247 s in hydronephrosis and failure to develop a patent pelvic-ureteric junction.

248 During the patent phase of Schistosoma mansoni infection, Foxp3(+)

249 ew innovation bonds, administrative savings, patent pools, and public-private risk sharing collaborat

250 At all time points, the struts along the patent portions of the aneurysm necks harbored scattered

251 are, in turn, significantly correlated with patent production.

252 Patent protection for several LMWH has expired and abbre

253 The current patent protection regime and its suitability in dealing

254 K9i drug price of $14300, with a lapse in US patent protection that would reduce the price by 43% in

255 Patent protections and market exclusivity, while serving

256 Drawing on millions of papers and patents published over 30 years, we use this model to in

257 nvoluntary acquisition of the pharmaceutical patents pursuant to federal statutory authority and prin

258 The overall survival time of completely patent PV and incomplete patent PV immediately after TIP

259 time of completely patent PV and incomplete patent PV immediately after TIPS was 57.05 +/- 0.75 vs.

260 omosis was performed in 4 cases of small but patent PV.

261 tion (LRVL) is another option but requires a patent PV.

262 to the briefly occluded in comparison to the patent radial artery of 0.802.

263 t decade, the number of molecules claimed in patent records by major pharmaceutical companies has dra

264 ribute to onward transmission and subsequent patent recrudescence.

265 search, from both scientific literatures and patents, related to the compaction of TMUPS.

266 a and ovarian cancer risk among women with a patent reproductive tract was 1.13 (95% CI, 1.01 to 1.26

267 interaction comparing women with vs without patent reproductive tracts was .15.

268 Compounds from these patent series, including PF 06882961, are currently in c

269 Exemplars from a patented series of GPR84 antagonists were able to block

270 ese include reverse payment or pay-for-delay patent settlements, authorized generics, product hopping

271 atients, 29 were excluded (17 because of non-patent small bowel).

272 S. mansoni egg-induced pathology during the patent stage of infection.

273 hile preserving cell-cell junctions, forming patent structures that support blood flow.

274 agents containing nitro groups, along with a patent survey on hypoxia-activated prodrugs containing n

275 ed in virtual screening, retrieving recently patented sweeteners and providing novel predictions.

276 nce, more particularly CHEMDNER and CHEMDNER patents tasks of BioCreative IV and V, respectively.

277 ormation contained in scientific literature, patents, technical reports, or the web is a pressing nee

278 tically, and show that 'complex' products or patents tend often to be those that countries rarely pro

279 with hypoplastic heart defects, compared to patents the proband's iPSC-CMs exhibited reduced prolife

280 as well as SureChEMBL for recent PDE related patents, to provide a wider context for exploring fragme

281 ur indicators of creative output: registered patents, trademarks, feature films produced, and baby-na

282 Here, we compare the outcome of patents treated within the Veterans Health Administratio

283 Linked papers and patents typically stand 2 to 4 degrees distant from the

284 126 patients (77 males and 49 females) with patent umbilical vein and signs of portal hypertension d

285 "products of nature" were not eligible to be patented unless they were "isolated and purified" from t

286 tion coexisted with other anomalies, such as patent urachus, Meckel's diverticulum, mesenteric cyst,

287 lvis; a site of VEGF-C expression, to form a patent vascular plexus.

288 Follow-up ultrasound demonstrated patent vasculature without evidence of thrombosis or out

289 ion is suppressed and maintains a quiescent, patent vasculature.

290 anatomy, such as those with a last remaining patent vessel (LRPV), are increasingly revascularized wi

291 he ablation zone, largely along persistently patent vessels.

292 ge, Sources page, Bioactivity dyad pages and Patent View page.

293 The excluded aneurysm sac shrank with patent visceral branches and there was an absence of end

294 million research articles and 3.9 million US patents, we find a substantial impact advantage of teamw

295 about 1% increase of the regional low-carbon patents, while a similar increase from large non-ETS fir

296 logical assessment, revealed both BRSs to be patent with nonobstructive neointimal hyperplasia.

297 Airway lumens remained patent with viable cells for one month in vitro with evi

298 raphy at 1 month showed that all shunts were patent, with no thrombosis or migration.

299 Patent WO2014151616A1, 2014), a selective B/C RAF inhibi

300 describe 15 (LXH254, Aversa, R.; et al. Int. Patent WO2014151616A1, 2014), a selective B/C RAF inhibi